



PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 70204

Title: Combined targeted therapy and immunotherapy in anaplastic thyroid carcinoma with distant metastasis: A case report

Provenance and peer review: Unsolicited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05223758

Position: Peer Reviewer

Academic degree: MD

Professional title: Attending Doctor

Reviewer's Country/Territory: Spain

Author's Country/Territory: China

Manuscript submission date: 2021-07-26

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-08-24 21:32

Reviewer performed review: 2021-08-26 19:28

Review time: 1 Day and 21 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

This is an interesting case report about a less common thyroid malignancy. The authors provide sufficient information about the clinical case. They have described in detail the patient's process, as well as the reasons why oncospecific treatments were suspended or maintained. Also, authors presented a good review of the current data of the topic. I consider it a great example of the alternatives offered by the combination of two treatments with different mechanisms of action such as immunotherapy and targeted therapy. I would like to ask a few questions and suggestions: - Did you consider the possibility of Radiosurgery of the cerebellar mass? And if not, why? - It seems contradictory that you named several immune related adverse events suffered by the patient, but you decided to discontinue Cabozantinib. I imagine that it is due to VEGFR-TKI toxicity. I recommend that you name and grade them. - To my knowledge, there is not an standard-of-care approval for combined immunotherapy and TKI in thyroid carcinoma. Why did you selected Cabozantinib and Nivolumab and not other TKI or PD-1 / PD-L1 inhibitor? Maybe there is an early trial in your region, it may be interesting to cite it. - As a suggestion, it could be helpful a graphic including all treatments received with data of start and finish, as the PFS of each therapy